Form 4: Genpact CEO Balkrishan Kalra Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Genpact's CEO, Balkrishan Kalra, exercised stock options and sold shares on March 13, 2025, according to a pre-arranged 10b5-1 trading plan.
Summary
- Balkrishan Kalra, the President and CEO of Genpact LTD, executed a transaction involving company stock on March 13, 2025.
- Kalra exercised employee stock options to acquire 13,600 common shares at an exercise price of $27.65.
- Simultaneously, Kalra sold 13,600 common shares at a weighted average price of $48.89, with prices ranging from $48.70 to $49.13.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Kalra directly owns 310,246 common shares and 42,800 derivative securities (employee stock options).
Sentiment
Score: 5
Explanation: The document simply reports stock transactions by an executive under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows executives to sell shares in a predetermined manner, avoiding accusations of insider trading. These transactions are closely watched by investors for insights into management's perspective on the company's value.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- The vesting schedule of the options (50% on January 10, 2019 and the remainder on January 10, 2021) is a typical vesting arrangement.
- The use of a 10b5-1 trading plan is a standard practice among executives to manage their stock sales in a compliant manner, similar to practices seen at companies like Accenture and Infosys.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| January 10, 2019 | 50% of the employee stock options vested. |
| January 10, 2021 | The remainder of the employee stock options vested. |
| September 13, 2024 | Date the reporting person adopted the Rule 10b5-1 trading plan. |
| March 13, 2025 | Date of the reported transactions: exercising stock options and selling shares. |
| March 31, 2026 | Expiration date of the employee stock options. |
| March 14, 2025 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.